Pesquisar
Adaptimmune Therapeutics PLC
ADAPAdicionar à lista de desejos
0.055USD
0.0000.00%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
10.34MValor de mercado
PerdaP/L TTM
Mais detalhes de Adaptimmune Therapeutics PLC Empresa
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Informações de Adaptimmune Therapeutics PLC
Código da empresaADAP
Nome da EmpresaAdaptimmune Therapeutics PLC
Data de listagemMay 06, 2015
CEORawcliffe (Adrian George)
Número de funcionários506
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 06
Endereço60 Jubilee Avenue
CidadeABINGDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalOX14 4RX
Telefone441235430000
Sitehttps://www.adaptimmune.com/
Código da empresaADAP
Data de listagemMay 06, 2015
CEORawcliffe (Adrian George)
Executivos da empresa Adaptimmune Therapeutics PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Adaptimmune Therapeutics PLC?
Os cinco principais acionistas de Adaptimmune Therapeutics PLC são: Dr. Garry E. Menzel, Ph.D.
Quantas instituições possuem ações da Adaptimmune Therapeutics PLC (ADAP)?
Em 2026Q1, 159 instituições possuíam ações da Adaptimmune Therapeutics PLC, com valor de mercado aproximado de 1.79M, representando 0.67% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -156325066.00.